



### About this pathway

This integrated care pathway has been created as a collaborative effort – our special thanks to the spinal muscular atrophy (SMA) professionals representing a range of specialist SMA centres who contributed to this project. We hope the pathway will be a useful resource locally for both healthcare professionals and providers to map the SMA journey and best practice care. We are particularly keen to share this resource and receive comments in order to ensure the pathway is as comprehensive as possible.

Currently awareness of SMA and access to SMA services across the UK is variable. As a result many individuals may wait too long for reviews and assessment which can have major ramifications for their symptom management and quality of life. It is essential that the complexity of SMA care is understood in order to make the most meaningful improvements to local services. We hope this integrated care pathway will help to unravel the SMA journey and aid you in improving and streamlining the care delivered in your area.

Standards of care are already available but granularity around the patient journey is important for specialists and generalists so that they can understand the care adults with SMA are likely to need throughout their journey. If the pathway is explicit, then:

- Patient journey is smoother
- Teams can ensure the right care is delivered at the right time.

### **International Standards of Care**


- Part 1: Diagnosis and management of spinal muscular atrophy: <u>Recommendations for diagnosis, rehabilitation, orthopedic and</u> <u>nutritional care – ScienceDirect</u>
- Part 2: <u>Diagnosis and management of spinal muscular atrophy:</u> <u>Pulmonary and acute care; medications, supplements and</u> <u>immunizations; other organ systems; and ethics - ScienceDirect</u>

The SMA integrated care pathway is easy to navigate by clicking on the menu tabs.

Click on icons in the pathway to open further information:



The pathway is designed to be viewed electronically. Some links redirect to resources that will open in your internet browser – these will require an internet connection.



SMA subtypes & expectations

About us

### **About SMA**

Spinal muscular atrophies (SMA) include a group of neuromuscular disorders characterised by degeneration of alpha motor neurons in the spinal cord with progressive muscle atrophy, weakness and paralysis. The most common form of SMA is due to a defect in the survival motor neuron 1 (SMN1) gene localised to 5q11.2-q13.3. It includes a wide range of phenotypes that are classified into clinical groups on the basis of age of onset and maximum motor function achieved.

Approximately 1 in 40 people carry an SMA-associated genetic mutation in the survival motor neurone 1 gene (SMN1) leading to an insufficient production of full length SMA protein. As a result 1:10,000 infants is born with the condition. The majority of infants with SMA have the most severe form of the disease (SMA I) in which symptoms manifest in the first few weeks or months of life. Milder forms of the disease also exist, e.g. SMA II, III and IV, which are associated with later onset and better prognosis. With available treatments the SMA phenotype classification is evolving towards a functional status definition:

# **Management of SMA**

SMA is managed through multidisciplinary supportive care. Treatment should follow guidelines from the International Standards of Care Committee for Spinal Muscular Atrophy. Supportive care strategies aim to minimise the impact of disability, address complications and improve quality of life. These may involve respiratory, gastroenterology, and orthopaedic care, as well as nutritional support, physiotherapy, assistive technologies, occupational therapy and social care. New treatments now present opportunities to change the management and survival landscape of SMA.


### **Treatment expectations**

Treatment expectations are subjective and based on each individual patient. To make sure the right treatment expectations are set a broad and holistic understanding of each patient's needs is required. These relate to: treatment access, access to supportive care, education level, geography, social isolation, information, peer-to-peer exchange and access to technology.

# What does it mean for patients and carers?

- Functional improvement from baseline any improvement is good. SMA is a deteriorating disease, so even stabilisation is seen as beneficial.
- Reduced manifestations.
- Improved life expectancy and stabilisation.





### Acknowledgements

Our thanks to the following individuals who contributed to the development of the integrated care pathway:

- · Hayley Davis, Neuromuscular physiotherapist, Cardiff and Vale University Health Board
- Rebecca Flesher, Occupational therapist, The Walton Centre NHS Foundation Trust, Liverpool
- Dr Clare Galtrey, Consultant neurologist, St George's Hospital London
- Dr Channa Hewamadduma, Neuromuscular physician, Sheffield Teaching Hospitals NHS Foundation Trust
- Natasha Hoyle, Neurosciences pharmacist, Sheffield Teaching Hospitals NHS Foundation Trust
- Dr James Lilleker, Neurology consultant, Salford Royal NHS Foundation Trust, Salford
- Lindsay Maidment, Neuromuscular clinical specialist physiotherapist, Sheffield Teaching Hospitals NHS Foundation Trust
- Dr Chiara Marini-Bettolo, Consultant neurologist, John Walton Muscular Dystrophy Research Centre, Newcastle
- Dr Andria Merrison, Consultant neurologist, North Bristol NHS Trust, Bristol
- Robert Muni-Lofra, Consultant physiotherapist, John Walton Muscular Dystrophy Research Centre, Newcastle
- Sun Narayan, Neuromuscular specialist physiotherapist and clinical coordinator, University Hospital Southampton NHS Foundation Trust

#### Facilitator

• Sue Thomas, Independent Healthcare Consultant

### Pathway design

• Sarah Mehta, Medical Writer


# **Contact us**


Please contact us with your comments and feedback at: info@neurologyacademy.org

Document due for review in November 2021.

Centres involved in the development of this pathway:

- Cardiff and Value University Health Board
- John Walton MND Research Centre, Newcastle
- Sheffield Teaching Hospitals
- Salford Royal NHS Foundation Trust
- St Georges Hospital, London
- The Walton Centre NHS Foundation Trust, Liverpool
- University Hospital Southampton
   NHS Foundation Trust







#### Nusinersen (Spinraza)

Nusinersen is provided under a Managed Access Agreement (MAA). The drug is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length, more functional SMN protein. Administered intrathecally, it is the first drug to have been licensed for the treatment of 5q SMA. Clinical trials have shown significant improvement in motor function with children who have been treated enabling them to achieve motor milestones that are unprecedented in the natural history of the condition. The drug has demonstrated efficacy in treated children and clinical trials have also highlighted that there may be a benefit in patients who start treatment earlier.

In July 2019, NICE, Biogen and NHS England came to an arrangement for the MAA, which allows children and adults with SMA Types I, II and III to have the treatment in England if they meet access criteria. The MAA is an interim scheme that enables data collection on treatment effectiveness whilst ensuring treatment access. The Spinraza agreement has been granted for five years and currently runs to 2024.


- <u>NICE (2019) MAA for nusinersen</u>
- <u>NICE (2019) Nusinersen for treating spinal muscular atrophy. Technology</u> <u>appraisal guidance [TA588]</u>


#### **Risdiplam (Evrysdi)**


Risdiplam is provided under the Early Access to Medicines Scheme (EAMS). This drug is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. This small molecule targets and encourages the SMN2 'back-up' gene to produce a greater amount of functional SMN protein, which is lacking in people with SMA.

Risdiplam is being studied in a broad range of patients who have SMA from birth to 60 years of age. It is an orally-administered liquid designed to provide a sustained increase in SMN protein centrally and peripherally when given daily at home in liquid form by mouth or by feeding tube making it suitable for when patients may not be able to tolerate intrathecal injections or eligible for nusinersen.

- <u>NICE technology appraisal: Risdiplam for treating spinal muscular atrophy in</u> <u>children and adults (publication expected July 2021)</u>
- Further information about EAMS
- The EAMS scheme is now closed to new patients following marketing authorisation from the MHRA (May 2021). Existing patients participating in the EAMS can continue to be treated until reimbursement.







#### Neuromuscular management

A multidisciplinary team approach is the key element in management of people with SMA and the different aspects of care should not be dealt with isolation but as part of a <u>MDT</u> approach. A coordinator should be available to coordinate all aspects of care. The diagnosis and management of SMA recommendations for care highlight an approach for management that addresses the needs of:

- Non-sitters
- Sitters
- Ambulant patients.


The key to all management is a baseline assessment and regular review of the person's individual ability (see <u>SMA outcome measures</u> and <u>measures evaluated in clinical trials</u>). Any improvement is good.

Rehabilitation: physiotherapy, occupational therapy, speech and language therapy

- Contracture management
- Movement abilitation
- Equipment/adaptations
- Swallow management.


Respiratory rehabilitation and management:


- Baseline respiratory assessments
- · Individualised respiratory care plans
- · Routine follow up including sleep studies
- When appropriate, use BiPAP and/or cough assist
- · Training on management of emergencies.



#### Multidisciplinary approach.

Source: Mercuri E, Finkel RS, Muntoni F et al (2017) Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care





Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary
Overview	Orthop	aedic & spine	<u>Respiratory</u>		Motor	Nutrition, GI & bone healt
Acute care						
		Pulmonary as	ssessment, intervent	ion and manageme	nt:	
Non-sitters		Sitters			Ambulant	
<ul> <li>Assessment of hypovent</li> <li>Sleep study or pneumog determine if NIV initiatio</li> <li>Assessment of gastroeso</li> </ul>	rams in all symptomatic pation needed.	symptor	try udy or pneumograms when r ns of nocturnal hypoventilati ent of gastroesophageal refl	on.	<ul> <li>Review of cough effect</li> <li>Detailed search for signal</li> </ul>	ctiveness. gns of nocturnal hypoventilation.
Support airway clearance: • Oral suctioning.		bronchodila	pronchodilators with asthma ator response	or a positive	Nebulised bronchodilators	in patients with suspicion of asthma
<ul> <li>Physiotherapy/respirato immediately: Manual ch</li> <li>Cough insufflator/exsuff</li> </ul>			, influenza vaccination annua	ally		uenza and pneumococcal vaccination.
Assessments 3 months i		physiothera	physiotherapy/respiratory th py Cough insufflator/exsuffla		Mucolytics should not be	used long-term.
<ul> <li>Airway clearance with p</li> <li>Cough assist essential w</li> </ul>	nysiotherapy/respiratory the th ineffective cough.		s 6 monthly, airway clearanc	e is critical with ineffective	Referral to respiratory te • Evidence of weak cou • Recurrent infections	
Support ventilation with bil	evel NIV in symptomatic pati	ents.			Suspicion of nocturna	l hypoventilation
			using it during acute respirat ally for adequate gas exchang		Source: Mercuri E, Finkel RS	5, Muntoni F et al (2017) Diagnosis and manageme spinal muscular atre
be fitted by skilled physioth	erapists selecting two interfa	ces to alternate skin contact	points.			« Back


Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary	
Overview	Orthopa	aedic & spine	Respiratory		<u>Motor</u>	Nutrition, GI &	bone health
Acute care							
			Physiotherapy ar	nd rehabilitation			
Non sitters		Sitters			Aambulant		
<ul> <li>joints, optimise function and positions, lying or sitting with physiotherapist and occupat</li> <li>Positioning, bean bags, we sitters.</li> <li>Custom made seats, recling help provide support.</li> <li>Stretching: flexibility is in Assisted stretches.</li> <li>Splints to support or Splints should be appovernight.</li> <li>Braces used to support.</li> <li>Neck collars: helpful for help they also help with bone</li> </ul>	immobilise limbs or spine plied for more than 60 minute ort part of the body for stabilis d at least 5 times a week. lead support and to assist brea help maintain and improve po health and digestion. n water can be helpful providir	nt and prevent s should give g	ective is to reduce impact an scoliosis. physiotherapy and o uidance and training on how to support arms, leg and spi ctivities such as standing and stabilise use minimum x 5 w <b>d braces</b> : keep joints in certa 50 mins or overnight. <b>bort and supported standing</b> ure increases bone density, k on. 60 mins minimum 3–5 tir nded g: combining effective stretch exercises is crucial. Routine sk by physiotherapy or occup and exercise: all sitters should r and custom seating, mobili ise will maintain and improve and balance and improve pa a and social activities. Resistant ng and wheelchair sports are e in exercise.	boccupational therapy to achieve aims. Ine to assist movement or supported walking. reekly. In positions should be stretches legs, promotes blood circulation and eases mes weekly, 5–7 times is thes with splints and hould be adapted ational therapy 5–7 times d have a powered ty aids and an accessible e strength, flexibility, rticipation in school and noce training, swimming,	<ul> <li>The overall aim is to promin day-to-day activities incomparison of the second second</li></ul>	heelchairs or ones with pow be tiring to walk. or scooters for long distanc ronment at home, educatio	ndependence d recreation. ovement: ce. wer-assisted

Introduction	SM	A pathway	Assessment	Treatment	Manage	ement	Resources	Glossary
Overview		Orthop	paedic & spine	Respiratory			Motor	Nutrition, GI & bone health
Acute care								

### Key messages

- Safe swallowing is one of the most important aspects of care as patients with a weak swallow are at risk of inhaling (aspirating) their food which can cause choking and chest (respiratory) infections.
- Review with speech and language therapist annually.
- Standards of Care recommend that a dietician reviews feeding and diet annually.
- If swallowing becomes unsafe, or if the patient is not maintaining their weight, feeding alternatives may be suggested:
  - Short-term options may include feeding through a:
    - Nasogastric (NG) tube a thin flexible feeding tube passed through the nose into the stomach.
    - Nasojejunal (NJ) tube through the nose into the middle part of the small intestine (the jejunum).
  - A longer-term option is:
    - Gastrostomy (PEG) tube placed in the stomach via a surgical procedure and also called a PEG - percutaneous endoscopic gastrostomy. Another procedure called a Nissen Fundoplication, which helps to reduce any reflux, may be done at the same time.

Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary
Overview	Orthop	aedic & spine	Respiratory		Motor	Nutrition, GI & bone he
Acute care						
	Nut	ritional assessment	, swallowing and gas	trointestinal dysfun	ction and interventio	n
Non-sitters		Sitters			Aambulant	
in aspiration and pulmon		Assessme	nt of symptoms of dysphag ing. Video fluoroscopic swa		<ul><li>Dietician assessment</li><li>See dietitian if over,</li><li>Nutritional analysis,</li></ul>	/under nutrition /monitoring if underweight or
Oral feeding may be limit Interventions – failed sw	ted. allow study <u>NG tube</u> or <u>NJ t</u>	records/fe	sestive of dysphagia. Nutrit eeding regimen, longitudin veight, OFC). Nutrition tabs	al anthropometrics	<ul><li>overweight</li><li>Longitudinal anthro</li></ul>	pometrics (height, weight, BMI, OF 1 labs 25 hydroxy-vitamin D tablets
Adequate hydration and during illness.	electrolyte balance import		itoring glucose metabolism ody composition and bone of		Bone health important	
when suggested by clinic	ow study shortly after diagr al signs suggestive of dyspl	nagia intake rec	ion management – evaluat commended for constipatic		DEXA scan     Speech and language assess	
(pocketing, jaw contracto Nutritional analysis of for anthropometrics, acute o D tabs, body composition	are monitoring 25 hydroxy and bone density.	-vitamin Dietician Possibility annually c	evaluation for concerns of of obesity check BMI. Diet or more often if required. N lised diets.	ician assessment	<ul> <li>Assessment of symptom feeding.</li> <li>Video fluoroscopic swall suggestive of dysphagia.</li> <li>Nutritional analysis of fc</li> <li>Longitudinal anthropom</li> </ul>	is of dysphagia, aspiration, difficulties with ow study if suggested by clinical signs
based on growth. Standa	ermine appropriate calorie rdised growth charts to tra ation with body compositio	needs ick on	with SMA are at risk of hypo	glycoomia: following	Minimise fasting during     on prior nutritional statu	rie intake and maximise nutrient intake. acute care. Appropriate fasting time depen us and nature of acute event.
	ually. NB Evaluation essenti	period of vo	omiting or fasting ensure suf		<ul> <li>Provide adequate fluid i and correct as needed.</li> </ul>	ntake during illness. Monitor electrolyte le
important for those on s	pecialised diets.	Sour	ce: Mercuri E, Finkel RS, Muntoni F e	t al (2017) Diagnosis and managem	<ul> <li>ent of spinal muscular atrophy</li> </ul>	« Back Next



Introduction	SM	A pathway	Assessment	Treatment	Manage	ement	Resources	Glossary	
Overview		Orthop	paedic & spine	Respiratory			Motor	Nutrition, GI &	bone health
Acute care									

### Acute care

Chest infections and breathing issues are the most frequent problems that require acute or emergency care.

There should be an emergency healthcare plan or illness plan in place written by the medical team including the following information:

- Brief summary of the individual's diagnosis/es and their understanding of it.
- What are the warning signs or indications that the patient should be taken to hospital?
- Which healthcare providers should be contacted in an emergency?
- A list of regular and PRN medications, and indications for any rescue medications left in the patient's home for emergency use.
- Any ceilings of care that have been requested by the patient and any that have been recommended by healthcare professionals.
- Describe actions for emergencies arising at home.
- Preferences around respiratory management and preferences for supported breathing i.e. NIV / intubation.
- Any neck or jaw limitations.
- Nutrition and fluids requirements.
- Techniques used for clearing secretions.
- When and which antibiotics should be given.
- Action agreed if resuscitation is required.
- Individual wishes of the patient.

Where possible, local emergency medical services should be contacted in advance to discussed any specific needs and what equipment is used at home. In an emergency, you should go to the closest hospital. Wherever possible, the equipment used at home should also be used, even if this is in an ambulance that is well equipped. Sometimes non-sitters and sitters may need to be transferred between hospitals as they should be cared for at a specialist (tertiary) centre that is equipped to look after them. The clinical team responsible for their long-term care should always be notified about the illness.

### **Further reading**

- Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- NICE (2019) Nusinersen for treating spinal muscular atrophy. Technology appraisal guidance [TA588]
- NICE (2016) Transition from children's to adults' services for young people using health or social care services [NG43]
- NICE technology appraisal: Risdiplam for treating spinal muscular atrophy in children and adults (publication expected July 2021)
- Care Quality Commission (2014) From the pond into the sea: Children's transition into adult health services


# Organisations

- Muscular Dystrophy UK <u>www.musculardystrophyuk.org</u>
- SMA Reach UK <u>www.smareachuk.org</u>
- Spinal Muscular Atrophy UK <u>www.smauk.org.uk</u>
- Royal College of General Practitioners <u>www.rcgp.org.uk</u>

# Glossary of abbreviations

BiPAP	Bilevel positive airway pressure
CT scan	Computerised tomography scan
EHP	Emergency healthcare plan
EAMS	Early Access to Medicines Scheme
EMG	Electromyogram
MAA	Managed access agreement
MDT	Multidisciplinary team
MRI	Magnetic resonance imaging scan
NICE	The National Institute for Health and Care Excellence
NIV	Non invasive ventilation
NG tube	Naso-gastric tube
NJ tube	Naso-jejunal tube
NM	Neuromuscular
OFC	Occipito-frontal circumference
ОТ	Occupational therapy
RSV vaccine	Respiratory syncytial virus vaccine
SCR	Shared-care record
SLA	Service level agreement
SMA	Spinal muscular atrophy

Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary	
	n the system and enter adult se erred in for assessment for one				Ongoing management		
In young people of paediatric to adult transition progration often described at Differences in Engaging with Difficulty identic clinics.	<b>from paediatric to adu</b> with chronic disabilities lik It care is often difficult if s mmes are not in place. Th as 'challenging and scary'. vigate a new and complex information provision and unfamiliar specialists. tifying and accessing spec ssing funding and equipm e gaps and lack of suppor	ke SMA, the transition fro structured and supportiv the transition to adult care k healthcare system. d expectations. ialists and multidisciplination	re e is	Young perso or under usin social Overarching Transition	g health or care principles	oporting infrastructure	
Children's trar • NICE (2016) Tr	ommission (2014) From t isition into adult health se cansition from children's to nealth or social care servic	ervices p adults' services for you	ing	Support befo			



### Psychological support and genetic counselling

- Psychological support for coming to terms with the diagnosis.
- What to expect from treatment and management.
- Genetic counselling, e.g. around family planning.

Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary
Patients may already be in t transition pathway or referr available for SMA					Ongoing management	
	Transitio to adult			SI	pecialist management	Ð

# **GP** role

While the GP is not the primary point of contact for patients because they lack the necessary expertise, they can play a role in SMA care and the relationship is key in terms of delivering a quality service throughout a patient's life. Currently patients tend to bypass GPs altogether and go straight to the paediatric / neuromuscular specialist centre for help. However, with GP education and a comprehensive care plan, GPs can certainly be more engaged in supporting SMA patients with:


- Vitamin D prescription
- Importance of vaccinations including the specific types (e.g. <u>RSV vaccine</u>, although a change in national guidance is also needed here).
- Antibiotic prescriptions (GPs need training on the longer period recommend for these patients [10–14 days] and the low threshold for prescription for patients with frequent chest infections).

Each patient should have a shared care plan in place which indicates which symptoms they should contact their GP about (with accompanying advice for the GP) and which should be directed towards the paediatric/specialist centre.

Each patient should have a separate emergency care plan.


Community nurses can assist with: providing suction, be available to do swabs or take samples if required, NG replacement, and providing nebuliser machine.

Currently it appears that service level agreements (SLAs) are informal and shared-care records (SCRs) are not in place. This needs to change if there is to be effective working between the specialist centre and local teams.



### **Objectives for SMA service**

- 1. Provide a specialist multidisciplinary neuromuscular service for diagnosis and ongoing management.
- 2. Initiate appropriate pharmacological and non-pharmacological treatments for patients with SMA.
- 3. Reduce morbidity and mortality due to SMA including reducing hospitalisation.
- 4. Ensure equity of access to specialised therapies.
- 5. Oversee all aspects of care that fall outside the expertise of local units.
- 6. At an individual level ensure the commissioning service is responsible for minimising disease impact in SMA.




# Audit points

- Timing of referrals:
  - Urgent referral within 1 day to 3 weeks depending on severity.
- Patient satisfaction questionnaire (local document) covering:
  - Patient made aware of identified timeframes.
  - Contact details at first consultation are made available to patient and their carers.
  - Patient received list of patient information at first consultation.
  - Patient referred for specialist medication (if appropriate) and received information leaflet about the medication detailing side effects and instructions about monitoring.

Introduction	SMA pathway	Assessment	Treatment	Management	Resources	Glossary
	he system and enter adult se ed in for assessment for one				Ongoing management	
	Transitio to adult care pathway			•	oecialist management Orthopaedic & spine Respiratory Nutrition • Moto	<b>+</b>


### Key performance indicators

- Identified benefit to patients.
  - Equity of access.
  - Appropriate referral pathway based on evidenced-based clinical assessment.
  - Access to the specialist team.
  - Patient has understanding of prognosis, available treatment and outcomes.
- Benefit to health professionals and organisation.
  - Appropriate referral and prioritisation of patient care achieved.
  - Standardisation of assessment and referral process.
  - Relevant investigations and patient information available, reducing delayed in patient journey later in pathway.
  - SMA MDT coordinator to liaise and respond directly with health professional and patient/carer regarding referral enquiry, waiting list management and liaise with the appropriate SMA team member to provide supportive information.
  - Cost and time effective management.
  - Clearly defined diagnostic process to follow.
  - Appropriate use of professional expertise and designated discussion time.
  - Clearly defined roles and responsibilities of the health professionals involved in the pathway.



Referral

There may be a video consultation 'pre-screen' at this point to establish when the patient was last seen, discuss potential genetic testing to confirm diagnosis and the implications of having treatment.



 $\otimes$ 

### Assessment


This may require a genetic test to confirm diagnosis if the patient has not been seen for some time. SMA Type 4, the more common form of adult onset SMA, is most often diagnosed in early adulthood. There are other forms of adult onset SMA with different causes. The impact of adult onset SMA varies greatly between individuals.

Getting a diagnosis of SMA Type 4 or other form of adult onset SMA can take time as the symptoms of SMA can seem similar to the symptoms of other neuromuscular conditions. Waiting for appointments, test results and a diagnosis can be very stressful. If you're concerned about your symptoms, have had some tests but have not been referred to a consultant neurologist, you might want to request a referral from your GP.

Possible tests are:


- An EMG which shows if the nerve supply is diminished.
- A muscle biopsy which shows if there is any reduction in muscle cells.
- An <u>MRI</u> scan which produces detailed images of the inside of the body.
- A <u>CT scan</u> which is another way of producing detailed images of the inside of the body.
- A range of blood tests, including a blood sample for DNA testing and baseline blood profile.
- Physiotherapy and respiratory assessment may also be required if the patient has not had a review for some time to ensure there are no comorbidities that might impact treatment.

Even with all these tests it's not always straightforward to say exactly what neuromuscular condition an adult has, though a specific diagnosis of SMA Type 4 can be made following DNA testing.



# Follow-up discussions about treatment and/or management options

Discussion about the full implications of intrathecal treatment, the requirement to have this administered in hospital (may necessitate spinal imaging by interventional radiology to assess access) and the impact on the patient's current routine.



 $\otimes$ 

### SMA REACH

SMA REACH UK is a two year study funded by a grant from SMA UK to Great Ormond Street Children's Charity. The project is a new initiative in collaboration with existing UK SMA registries – the UK SMA Patient Registry and SMArtNet Clinical Network UK sponsored by Muscular Dystrophy UK and Spinal Muscular Atrophy Support UK (formerly The Jennifer Trust). The SMA REACH UK project is led by the study team based at the Dubowitz Neuromuscular Centre, UCL.


The primary aim is to establish the first national clinical and research network: SMA REACH UK – SMA Research and Clinical Hub UK – to promote a national agreement on clinical and physiotherapy assessment and standards of care. The plan is to design, pilot and expand an electronic database created to streamline the collection of data for patients with SMA. This UK SMA database would be a unique infrastructure started at GOSH and Newcastle which will be accessible to specialist centres across the UK who treat patients with SMA.

The secondary aim of the project is to utilise the SMA REACH UK database as a longitudinal data store where information can be audited and reviewed. This will provide clinicians and researchers a rich resource of available information on a large collection of SMA patients. SMA Reach are collaborating with the Catholic University Rome, an international centre of excellence in SMA research and treatment, with the shared goal to facilitate translational research for this common neuromuscular disease in preparation to design national and international clinical trials. Once the system is finalised, additional national sites that have a history of successful SMA enrolment will be invited to participate and collect high quality longitudinal data.

This work will be an invaluable tool for the centres likely to be involved in upcoming SMA multicentre randomised clinical trials in SMA type I, II and III and ensure that the functional scales used are suitable and clinically relevant for future trials.

<u>SMA REACH</u> is the UK's SMA research and clinical hub UK focused on improving standards of care and translational research. It aims to establish national agreement on medical and physiotherapy assessments, and standards of care for patients with SMA in preparation for future clinical trials in the UK.

Read more on the SMA REACH website




### Anaesthetics

If the patient requires an anaesthetic the GP should alert the hospital if this is an elective admission to ensure the team in charge undertake:

- A review of the heart by a cardiologist (only if there is known to be a pre-existing problem)
- A full assessment before any anaesthetics are used. This may include a sleep study and involvement of a dietitian.
- Assessment of difficulties in intubating that may be caused by:
  - Tightening of the jaw
  - Limited neck mobility
  - Difficulties in positioning
- Monitoring blood carbon dioxide and oxygen at all times, whatever anaesthetic method is used.
- Anticipating any other possible needs such as use of NIV and other breathing interventions.
- Medication for pain management may be needed after an operation.

Considerations of local anaesthesia or regional analgesia; as a general rule anaesthesia does bring challenges.

Anaesthetics may be used for planned surgery as well as for other reasons, such as administering new drug treatments.



 $\otimes$ 

### Early Access to Medicines Scheme (EAMS)

The EAMS programme helps to give people with life threatening or seriously debilitating conditions early access to new medicines that do not have a marketing authorisation but where there is a clear unmet medical need. By promoting early engagement between pharmaceutical companies, and the Accelerated Access Consortium (AAC) partners including MHRA, NICE, NHS England and NHS Improvement, EAMS also helps to create a smoother route to market for new treatments. Since launch of the scheme in 2014 over 1,200 people with conditions ranging from cancer to Duchenne Muscular Dystrophy, from across the UK, have benefited from early access to new treatments through EAMS. Risdiplam is currently going through a NICE Health Technology Appraisal (HTA) and the expected publication date is in 2021. Patients currently accessing the drug now do so under the EAMS programme.

EAMS has been granted for risdiplam for type 1 or type 2 SMA who are not suitable for authorised treatments. EAMS scheme is now closed to new patients following marketing authorisation from the MHRA (May 2021). Existing patients participating in the EAMS can continue to be treated until reimbursement.

- https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams
- <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/918768/Risdipl</u> am Treatment\_protocol\_Information\_for\_patients.pdf



 $\otimes$ 

#### **SMA REACH**

SMA REACH UK is a two year study funded by a grant from SMA UK to Great Ormond Street Children's Charity. The project is a new initiative in collaboration with existing UK SMA registries – the UK SMA Patient Registry and SMArtNet Clinical Network UK sponsored by Muscular Dystrophy UK and Spinal Muscular Atrophy Support UK (formerly The Jennifer Trust). The SMA REACH UK project is led by the study team based at the Dubowitz Neuromuscular Centre, UCL.


The primary aim is to establish the first national clinical and research network: SMA REACH UK – SMA Research and Clinical Hub UK – to promote a national agreement on clinical and physiotherapy assessment and standards of care. The plan is to design, pilot and expand an electronic database created to streamline the collection of data for patients with SMA. This UK SMA database would be a unique infrastructure started at GOSH and Newcastle which will be accessible to specialist centres across the UK who treat patients with SMA.

The secondary aim of the project is to utilise the SMA REACH UK database as a longitudinal data store where information can be audited and reviewed. This will provide clinicians and researchers a rich resource of available information on a large collection of SMA patients. SMA Reach are collaborating with the Catholic University Rome, an international centre of excellence in SMA research and treatment, with the shared goal to facilitate translational research for this common neuromuscular disease in preparation to design national and international clinical trials. Once the system is finalised, additional national sites that have a history of successful SMA enrolment will be invited to participate and collect high quality longitudinal data.

This work will be an invaluable tool for the centres likely to be involved in upcoming SMA multicentre randomised clinical trials in SMA type I, II and III and ensure that the functional scales used are suitable and clinically relevant for future trials.

<u>SMA REACH</u> is the UK's SMA research and clinical hub UK focused on improving standards of care and translational research. It aims to establish national agreement on medical and physiotherapy assessments, and standards of care for patients with SMA in preparation for future clinical trials in the UK.

Read more on the SMA REACH website



#### Homecare

Homecare can be used to supply the drug. The homecare company can reconstitute the drug powder and deliver the resultant oral solution to the patient using cold chain storage. Risdiplam is supplied via the homecare pharmacy or specialist treatment centre. If risdiplam is supplied by the specialist treatment centre, they will:

- Provide sufficient risdiplam to take at home/outside of hospital setting.
- Provide instructions on how bottles can be transported home •
- Provide instructions on how to store and take the medication. •
- Supply oral syringes for medicine administration.

If risdiplam is supplied by homecare pharmacy, they will:

• Deliver sufficient risdiplam to the home or previously agreed address.

The patient is also provided with an "Instructions for use for patients/parents and carers" booklet. This booklet gives detailed instructions on how to prepare the dose volume with the re-usable oral syringes provided, and take the medicine either: by mouth, through a gastrotomy tube, or through a nasogastric tube.